Saracatinib

Saracatinib (AZD0530) is a potent Src family inhibitor with IC50s of 2.7 to 11 nM for c-Src, Lck, c-YES, Lyn, Fyn, Fgr, and Blk. Saracatinib shows high selectivity over other tyrosine kinases[1].

Product Specifications

CAS Number

[379231-04-6]

Product Name Alternative

AZD0530

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Autophagy; Src

Type

Reference compound

Related Pathways

Autophagy; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Saracatinib.html

Purity

99.28

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

ClC1=CC=C2C(OCO2)=C1NC3=C4C(OC5CCOCC5)=CC(OCCN6CCN(C)CC6)=CC4=NC=N3

Molecular Formula

C27H32ClN5O5

Molecular Weight

542.03

Precautions

H302, H315, H319, H335

References & Citations

[1]Green TP, et al. Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530. Mol Oncol, 2009, 3 (3), 248-261.|[2]Fuse MA, et al. Combination Therapy With c-Met and Src Inhibitors Induces Caspase-Dependent Apoptosis of Merlin-Deficient Schwann Cells and Suppresses Growth of Schwannoma Cells. Mol Cancer Ther. Mol Cancer Ther. 2017 Nov;16 (11) :2387-2398.